ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2266

Platelet-selectin Prime Lupus Neutrophils to Produce Mitochondrial ROS and Participate in SLE Pathogenesis

Marc Scherlinger1, Pierre Vacher2, Vivien Guillotin3, Isabelle Douchet4, Christophe Richez5 and Patrick Blanco4, 1BIDMC Harvard University, Boston, MA, 2INSERM U1218, Bordeaux, France, 3CHU de Bordeaux, Bordeaux, France, 4UMR-CNRS 5164 Immunoconcept, Bordeaux, France, 5CHRU Bordeaux, Bordeaux, France

Meeting: ACR Convergence 2022

Keywords: immunology, neutrophils, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: SLE – Etiology and Pathogenesis

Session Type: Abstract Session

Session Time: 5:00PM-6:00PM

Background/Purpose: In patients with active systemic lupus erythematosus (SLE), circulating platelets have an activated phenotype characterized by the expression of P-selectin (CD62P). We have shown that in human SLE, platelets interact with T regulatory cells and repress their immunosuppressive functions through a P-selectin/CD15s-dependent interaction (1). We sought to investigate for other platelet/immune cell interaction and their potential relevance in SLE.

Methods: Patients with SLE responding to the 2019 ACR/EULAR criteria were recruited for blood sampling (n = 30). The expression of CD15s (P-selectin ligand) was assessed on all circulating immune cell subset using flow cytometry. Platelet-neutrophils aggregates were identified as (platelet) CD61+ (neutrophil) CD66b+ cells using flow cytometry on fresh blood samples. Single-cell cytosolic calcium and ROS imaging was performed by incubating cell with either a fluorescent calcium dye (cali-520), or a mitochondrial specific dye (MitoSox). Platelet-free plasma was isolated by two sequential centrifugations (3500xg) of EDTA-anticoagulated blood and stored for subsequent evaluation of soluble P-selectin (using ELISA) and (platelet-derived) microparticular P-selectin using flow cytometry.

Results:

Results: In healthy donors (HD) and patients with SLE, circulating neutrophils expressed significantly higher levels of the P-selectin ligand CD15s compared to other immune subsets (p < 0.001), predicting platelet/neutrophil interactions. In contrast to HD and patients with inactive SLE, patients with active SLE had significantly more circulating platelet-neutrophils aggregates (p < 0.001; Fig. 1A-B), and these aggregates correlated with the SLEDAI (r = 0.59, p < 0.001; Fig. 1C). The incubation of human neutrophils with recombinant P-selectin induced a strong intracellular calcium signaling which was inhibited by an anti-PSGL1 antibody (blocking P-selectin/CD15s interaction) or with a Syk kinase inhibitor (Fig. 2A-B). Similarly, P-selectin induced a mitochondrial ROS release in a CD15s- and Syk-dependent manner (Fig. 2C). Interestingly, incubation of neutrophils with anti-dsDNA IgG and P-selectin induced mitochondrial depolarization, which was absent with either stimulus alone. Soluble and platelet-derived microparticular P-selectin levels were significantly increased in patients with active SLE compared to inactive patients or healthy donors (p < 0.05 and p < 0.001, respectively). In a longitudinal analysis of SLE patients, soluble and microparticular P-selectin levels closely followed clinical (SLEDAI) and biological (C3 levels) markers of SLE disease activity.

Conclusion: P-selectin levels are increased in active SLE and follow hallmarks of the disease activity. P-selectin induces calcium/mitochondrial ROS signaling in lupus neutrophils which are key players in SLE pathogenesis. We hypothesize that that platelet-neutrophil interaction participate in SLE pathogenesis and that blocking these interaction may represent a target in SLE.

Reference:
1) Scherlinger M. et al. (2021), Science Translational Medicine, 13(600):eabi4994.

Supporting image 1

Figure 1: platelet/neutrophils aggregates are increased in systemic lupus and correlate with disease activity.
Fresh blood was drawn from healthy donors and SLE patients (n = 30), and flow cytometry was conducted. (A) Gating strategy for the platelet/neutrophils aggregates (gated on CD66b+ cells). (B) Cumulative results for platelet/neutrophil aggregates. (C) Spearman correlation between platelet/neutrophil aggregates and the SLE disease activity index (SLEDAI). Each point represents one patient and bars indicate S.D. *, p < 0.05; ***, p < 0.001 using one-way ANOVA with Sidak's correction.

Supporting image 2

Figure 2: platelet-selectin induces a calcium release and mitochondrial reactive oxygen species production in neutrophils in a PSGL_1/Syk-dependent manner.
(A) Single-cell relative fluorescence using Cali-520 reflecting intracytoplasmic calcium concentration in healthy donors neutrophils stimulated with P-selectin (100ng/mL), with or without pre-incubation with anti-PSGL1 antibody or a Syk inhibitor. (B) Cumulative data of (A) experiment, each point represents one cell and bars indicate S.D; ****, p<0.001 using one-way ANOVA with Sidak's correction. (C) Single-cell MitoSox fluorescence representing intracellular mitochondrial reactive oxygen species in healthy donors neutrophils stimulated with P-selectin (100ng/mL), with or without pre-incubation with anti-PSGL1 antibody or a Syk inhibitor.


Disclosures: M. Scherlinger, Sandoz, Amgen, Nordic Pharma; P. Vacher, None; V. Guillotin, None; I. Douchet, None; C. Richez, None; P. Blanco, None.

To cite this abstract in AMA style:

Scherlinger M, Vacher P, Guillotin V, Douchet I, Richez C, Blanco P. Platelet-selectin Prime Lupus Neutrophils to Produce Mitochondrial ROS and Participate in SLE Pathogenesis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/platelet-selectin-prime-lupus-neutrophils-to-produce-mitochondrial-ros-and-participate-in-sle-pathogenesis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/platelet-selectin-prime-lupus-neutrophils-to-produce-mitochondrial-ros-and-participate-in-sle-pathogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology